Deepa Rangachari
Expertise in
16
conditions

Dr. Deepa Rangachari

Internal Medicine | Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
On Staff At
Offers Telehealth
Expertise in
16
conditions
330 Brookline Avenue, Shapiro 9, 
Boston, MA 

Overview

Deepa Rangachari is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Rangachari is highly rated in 16 conditions, according to our data. Her top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Thymectomy.

Her clinical research consists of co-authoring 86 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Chicago, Pritzker School Of Medicine

Residency

Johns Hopkins Hospital

Specialties

Internal Medicine
Oncology

Licenses

Internal Medicine in MD

Board Certifications

American Board Of Internal Medicine

Fellowships

Johns Hopkins Hospital

Hospital Affiliations

Beth Israel Deaconess Hospital - Milton
Beth Israel Deaconess Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Enrollment Status: Terminated
Publish Date: January 08, 2026
Intervention Type: Drug
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Enrollment Status: Unknown
Publish Date: February 07, 2022
Intervention Type: Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 1/Phase 2
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

86 Total Publications

Modernizing Medical Education: Educational Strategies to Meet Emerging Needs in Hematology/Oncology.
Modernizing Medical Education: Educational Strategies to Meet Emerging Needs in Hematology/Oncology.
Journal: JCO oncology practice
Published: December 12, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Matthew Davids
Oncology
Expertise in
21
conditions
Dr. Matthew Davids
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist in Boston, Massachusetts. Dr. Davids is highly rated in 21 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Tissue Biopsy, and Bone Marrow Transplant.

Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology
Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jacobsen is an Oncologist in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
28
conditions
Dr. Jeremy Abramson
Oncology
Expertise in
28
conditions
Dr. Jeremy Abramson
Oncology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Abramson is an Oncologist in Boston, Massachusetts. Dr. Abramson is highly rated in 28 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Deepa Rangachari

How do I make an appointment with Dr. Deepa Rangachari?

You can book an appointment with Dr. Deepa Rangachari by calling their office at 617-667-2174. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Deepa Rangachari a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Deepa Rangachari is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Deepa Rangachari specialize in?

While Dr. Deepa Rangachari is a Internal Medicine, they have specific expertise in Lung Cancer, EGFR Positive Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Deepa Rangachari participate in research or clinical trials?

Yes. Dr. Deepa Rangachari has published 86 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Deepa Rangachari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Deepa Rangachari accept my insurance?

Dr. Deepa Rangachari accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-667-2174 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rangachari's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile